ASH 2022 | MagnetisMM-3: elranatamab in R/R multiple myeloma naive to BCMA-directed therapy
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, describes the results from Cohort a of MagnetisMM-3 (NCT04649359), a Phase II trial investigating the efficacy and safety of elranatamab in patients with relapsed/refractory (R/R) multiple myeloma who are naïve to BCMA-directed therapies. Overall, the results indicated that elranatamab is highly effective and well tolerated in patients with R/R multiple myeloma, with durable responses achieved. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead: Honoraria; GSK: Honoraria; Pfizer,: Honoraria; Adaptive Biotechnologies: Honoraria; Oncopeptides: Honoraria; Astellas: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Amgen: Honoraria; Jazz Pharmaceuticals: Honoraria, Research Funding; Celgene: Honoraria; Bristol Myers Squibb: Honoraria; Sanofi: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.
